Literature DB >> 21387278

Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome.

Cristina Bozzao1, Patrizia Lastella, Maurizio Ponz de Leon, Monica Pedroni, Carmela Di Gregorio, Francesco D D'Ovidio, Nicoletta Resta, Fernando Prete, Ginevra Guanti, Alessandro Stella.   

Abstract

BACKGROUND: In patients with Lynch syndrome, germline mutations in DNA mismatch repair (MMR) genes cause a high risk of developing a broad spectrum of cancers. To date, the management of patients with Lynch syndrome has represented a major challenge because of large variations in age at cancer onset. Several factors, including genetic anticipation, have been proposed to explain this phenotypic heterogeneity, but the molecular mechanisms remain unknown. Telomere shortening is a common event in tumorigenesis and also has been observed in different familial cancers. In this study, the authors investigated the possibility of a relation between telomere length and cancer onset in patients with Lynch syndrome.
METHODS: The mean telomere length was measured using quantitative polymerase chain reaction in peripheral blood samples from a control group of 50 individuals, from 31 unaffected mutation carriers, and from 43 affected patients, and the results were correlated with both gene mutation and cancer occurrence. In affected patients, telomere attrition was correlated with age at cancer onset. In all patients, a t test was used to assess the linearity of the regression.
RESULTS: A significant correlation between telomere length and age was observed in both affected and unaffected mutation carriers (P = .0016 and P = .004, respectively) and in mutS homolog 2 (MSH2) mutation carriers (P = .0002) but not in mutL homolog 1 (MLH1) mutation carriers. Telomere attrition was correlated significantly with age at onset in MSH2 carriers (P = .004), whereas an opposite trend toward longer telomeres in patients with delayed onset was observed in MLH1 carriers.
CONCLUSIONS: The current data suggested that telomere dynamics differ between MLH1 and MSH2 mutation carriers. It is possible that subtle, gene-specific mechanisms can be linked to cancer onset and anticipation in patients with Lynch syndrome.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21387278     DOI: 10.1002/cncr.26022

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Fertility and apparent genetic anticipation in Lynch syndrome.

Authors:  Douglas Stupart; Aung Ko Win; Mark Jenkins; Ingrid M Winship; Paul Goldberg; Rajkumar Ramesar
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

2.  No evidence of genetic anticipation in a large family with Lynch syndrome.

Authors:  D Stupart; P Goldberg; U Algar; A Vorster; R Ramesar
Journal:  Fam Cancer       Date:  2014-03       Impact factor: 2.375

3.  Anticipation in lynch syndrome: where we are where we go.

Authors:  Cristina Bozzao; Patrizia Lastella; Alessandro Stella
Journal:  Curr Genomics       Date:  2011-11       Impact factor: 2.236

4.  Genetic anticipation in Swedish Lynch syndrome families.

Authors:  Jenny von Salomé; Philip S Boonstra; Masoud Karimi; Gustav Silander; Marie Stenmark-Askmalm; Samuel Gebre-Medhin; Christos Aravidis; Mef Nilbert; Annika Lindblom; Kristina Lagerstedt-Robinson
Journal:  PLoS Genet       Date:  2017-10-31       Impact factor: 5.917

5.  Human MLH1 suppresses the insertion of telomeric sequences at intra-chromosomal sites in telomerase-expressing cells.

Authors:  Pingping Jia; Megan Chastain; Ying Zou; Chengtao Her; Weihang Chai
Journal:  Nucleic Acids Res       Date:  2017-02-17       Impact factor: 16.971

6.  Telomere length and genetic anticipation in Lynch syndrome.

Authors:  Nuria Seguí; Marta Pineda; Elisabet Guinó; Ester Borràs; Matilde Navarro; Fernando Bellido; Victor Moreno; Conxi Lázaro; Ignacio Blanco; Gabriel Capellá; Laura Valle
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

7.  Longer telomeres are associated with cancer risk in MMR-proficient hereditary non-polyposis colorectal cancer.

Authors:  Nuria Seguí; Elisabet Guinó; Marta Pineda; Matilde Navarro; Fernando Bellido; Conxi Lázaro; Ignacio Blanco; Victor Moreno; Gabriel Capellá; Laura Valle
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.